0102 GMT - Sonic Healthcare gets a new bull at Bell Potter, where analyst Martyn Jacobs sees the pathology operator getting over what he calls its Covid-19 hangover. Jacobs initiates coverage of the stock with a buy rating, telling clients in a note that he expects Ebitda margins to start recovering from a rocky spell in FY 2025. Margins will expand by about 110 bps through fiscal FY he reckons. He says that growth is being driven by cost reductions, recent acquisitions, and a normalization of organic operations following Covid-driven disruption. Bell Potter puts a A$33.70 target price on the stock, which is up 1.0% at A$26.49. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
June 18, 2025 21:02 ET (01:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。